 MONROVIA, Calif. LOS ANGELES--BUSINESS WIRE--Xencor, Inc. NASDAQ:XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technology Development Group UCLA TDG today announced an agreement to develop novel therapeutic antibodies, pairing novel targets proposed by scientists at UCLA and utilizing Xencors modular suite of XmAb technology platforms. Xencor and UCLA have establi 